Uveal Melanoma study: Aldesleukin
Official title Adding IL-2 to Tebentafusp to Eradicate Cancer Progression
ClinicalTrials.gov ID: NCT07063875
What this study is testing
What is Aldesleukin (Proleukin)?
An investigational injectable medicine being studied for uveal melanoma.
Also referred to as Proleukin.
Plain-language explanation of the investigational treatment. It is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The study wants to see whether combining tebentafusp with IL‑2 can improve tumor shrinkage and overall survival, and to learn about the benefits and side effects of this combination.
- Who it's for
- It is looking for adults who have metastatic uveal melanoma, especially those whose cancer has spread to the liver.
- What's involved
- Participants will receive both IL‑2 and tebentafusp in a 28‑day cycle, with specific days for each drug as listed in the schedule. They will have regular visits for treatment and monitoring.
- Time commitment
- The trial lasts for multiple 28‑day cycles; participants will need to attend scheduled visits each cycle for drug administration and health checks.
- Phase 2: a mid-size study of how well it works
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Histologically or cytologically confirmed metastatic UM or unresectable UM patients
- HLA-A\ 02:01 positive
- Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1
- RECIST 1.1 defined progression on single-agent Tebentafusp, with no other intervening systemic therapies
You likely can't join if
- Presence of untreated or symptomatic central nervous system (CNS) metastases, leptomeningeal disease, or cord compression.
- Systemic treatment with steroids or any other immunosuppressive drug use within 2 weeks of the planned first dose of program intervention, with the...
- Any relevant medical condition, which in the opinion of the treating physician, would prevent the participant enrolling into the Program due to...
- Chronic viral infections as indicated below. NOTE: Testing for human immunodeficiency virus (HIV), hepatitis B virus (HBV), and hepatitis C virus...
The study team makes the final eligibility decision.
Where it is enrolling
- Sydney, New South Wales, Australia
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
This study is enrolling now at Sydney, New South Wales, Australia. Enter your location above to see the nearest enrolling site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.